VEGA: Guselkumab plus golimumab achieved higher clinical remission rates in UC

CHARLOTTE, N.C. — Guselkumab in combination with golimumab induced greater rates of clinical remission compared with monotherapy among patients with moderate to severely active ulcerative colitis.VEGA phase 2a proof-of-concept week 12 data showed dual blockade of interleukin (IL)-23 and tumor necrosis factor induced clinical response, clinical remission, endoscopic improvement and composite histologic-endoscopic outcomes more effectively than monotherapy alone, Brian G. Feagan, MD, senior scientific director of Alimentiv Inc. and gastroenterologist at Western University, reported at theRead More